Moderna has brought together a set of seasoned executives to realize our vision. In addition to having built companies that have successfully commercialized biotech products, we share a fascination with the possibilities of our science, and a desire to question everything in our pursuit of better solutions for patients.
Stéphane joined Moderna in the summer of 2011 when it was a one employee and one patent company, after Dr. Noubar Afeyan and the board described to him the technology behind messenger RNA Therapeutics™. He has assembled a world-class team and raised the company’s financing.
He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMerieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion. During his five years with bioMérieux, he accelerated the company’s sales growth rate from a historic rate of 4-5% per year to above 9% per year, grew EBIT at 12% CAGR (versus a historical growth rate of 4-5%), enhanced its position as the global leader in clinical microbiology and re-accelerated its immuno-assay franchise by focusing on high medical value biomarkers. He led the company through 10 successful acquisitions in the U.S., Europe, and Asia/Pacific without needing new capital from shareholders. During that time, the company’s market capitalization nearly doubled despite the 2008 financial crisis.
Prior to his time at bioMérieux, Stéphane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.
He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.
Stéphane is named as an inventor on over 45 patent filings in the field of messenger RNA technology. These filings include claims covering a broad range of novel compositions and formulations as well as manufacturing and clinical methods in the fields of human and animal therapeutics, diagnostics and cell processing.
Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Stephane serves as a Supervisory Director of Qiagen N.V., Executive Chairman of the Board of BG Medicine, Inc., and on the Board of Directors of Syros Pharmaceuticals.
As president of research and development (R&D), Dr. Joseph Bolen oversees all aspects of R&D at Moderna including discovery research, preclinical and clinical development, and clinical operations. Prior to joining Moderna, Dr. Bolen was the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company, where he held various senior positions beginning in 1999. He has also held leadership positions at Hoechst Marion Roussel and the Bristol-Myers Squibb Pharmaceutical Research Institute, and was the founding director of the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California.
Dr. Bolen brings a proven track record of leading a large and multi-faceted international R&D organization while fostering a culture of scientific innovation within a global commercial-stage company. He has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research since starting his career as a scientist at the National Institutes of Health (NIH).
Dr. Bolen has published more than 200 peer-reviewed scientific articles and book chapters, and has presented hundreds of lectures and seminars at leading universities, as well as at national and international scientific meetings. He has served on numerous journal editorial boards as well as study sections, panels and committees for the National Institutes of Health, the National Aeronautics and Space Administration, the Howard Hughes Medical Institute, the American Cancer Society, the American Association for Cancer Research and academic institution scientific advisory boards.
Dr. Bolen graduated from the University of Nebraska with a B.S. in Microbiology & Chemistry and a Ph.D. in Immunology. He pursued postdoctoral training in Molecular Virology at the Kansas State University Cancer Center where his research was directed towards analysis of the polyoma DNA tumor virus.
Axel leads new business concept activities. Axel has 15 years of experience and proven leadership in research and development, strategic business development and operational business management.
Axel joined Moderna in November from Bayer, where he served as Vice President Global Strategy of the Bayer HealthCare Group with responsibility for Pharmaceuticals, Consumer Care Products, Medical Devices and Animal Health. Prior to this, Axel was leading the operational business for Bayer HealthCare in Malaysia, Singapore and Brunei as Managing Director and established Singapore as a leading global R&D hub for Bayer with several local research collaborations. From 2007-2009, Axel was heading the global M&A department for the newly formed Bayer Pharmaceuticals Division. He successfully managed and closed several acquisitions, licensing and partnership deals.
During his scientific and medical career, Axel focused on oncology, neurology and inflammation at the German Cancer Research Center in Heidelberg, the Basel Institute for Immunology and the ETH in Zurich.
Axel studied Chemistry, Biochemistry, Medicine and Business Administration and holds a PhD from the Eberhard-Karls-University Tübingen in Immunology. In 2008, he completed the Executive MBA & Leadership Program of the IMS Business School in Lausanne, Switzerland..
Peter joins Moderna from Merck & Co., Inc. and brings to the table over 20 years of experience in the pharmaceutical industry, drawing from a legal and technical background that spans both biotech start-up and Fortune 100 settings. At Merck, Peter served as Managing Counsel of the Merck Mission Bay site in San Francisco and as Counsel for the Oncology division while based in New Jersey. Mr. Haeberli joined Merck following the acquisition of Sirna Therapeutics Inc. in 2006. At Sirna, Mr. Haeberli held the position of Director, Intellectual Property, where he was instrumental in the development of the company's intellectual property estate. Mr. Haeberli joined the predecessor to Sirna (Ribozyme Pharmaceuticals Inc.) in 1993 as a research chemist before transitioning to the legal department in 1999. He held positions of increasing responsibility through the restructuring and relaunch of the company in 2003, leading up to the 2006 acquisition. Prior to joining Ribozyme, Mr. Haeberli had chemistry roles with Ciba-Geigy Corp. and Geneva Pharmaceuticals Inc. in New Jersey and Colorado.
Mr. Haeberli graduated from the University of Colorado, Boulder, with a B.A. in Molecular, Cellular, and Developmental Biology and received his J.D., Order of St. Ives, from the University of Denver, Sturm College of Law. He is a member of the bar of the State of Colorado, and is admitted to practice before the United States Patent and Trademark Office.
Steve brings more than 30 years of diverse operational experience in pharmaceuticals and in-vitro diagnostics to his position at Moderna, having served in a variety of senior business and operational leadership roles both in Europe and the U.S. Prior to joining Moderna, he was the Corporate Vice President of Global Operations at bioMérieux, where he was responsible for more than 3,000 global employees over multiple global functions and manufacturing sites.
In his career Steve has held senior leadership positions driving strategic direction and performance in such areas as, manufacturing, information systems, quality, regulatory affairs and compliance. He has continually refined and reengineered internal processes driving transformation in response to new business challenges.
Steve has held leadership roles with Eli Lilly and Company, Shionogi Qualicaps (Spain), Elanco Qualicaps (U.K.) and Elanco Animal Health where his work covered many different dimensions from sales and marketing to HR and people development in highly regulated environments, resulting in receiving ‘best practice’ recognition from the FDA.
He graduated in 1979 from Durham College of Agriculture in the UK.
Stephen leads strategy, business development, and preclinical oncology for Moderna and is the inventor of several mRNA patents. Prior to Moderna, Stephen was a partner at McKinsey & Company and a leader in the firm’s Healthcare and Corporate Finance practices. At McKinsey Stephen advised senior management teams of leading biotech and pharmaceutical companies on a wide range of strategic, financial and operational issues. Prior to joining the firm, Stephen was a physician in New York. He holds an M.D. with thesis from the University of California, San Francisco, and a B.S. in Neuroscience from Amherst College.
Lorence joins Moderna from Goldman Sachs where he was a managing director and co-head of the U.S. biotechnology investment banking effort. He joined Goldman Sachs in 1999 as a summer associate, and was named managing director in 2008. As a member of the Healthcare Investment Banking Group for nearly 14 years, Lorence’s responsibilities included corporate finance and mergers and acquisitions (M&A) for the pharmaceutical and biotechnology industries, with several billion in equity and equity-linked financings, and more than $55 billion in M&A transactions.
Prior to joining Goldman Sachs, Lorence worked in various medical research and consulting positions concurrent with his graduate studies. Lorence graduated from Harvard University, magna cum laude and Phi Beta Kappa with an AB in Biochemical Sciences in 1995. He also earned an MBA in Healthcare Management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000, and an M.D. from the University of Pennsylvania’s School of Medicine in 2000.
Prior to joining Moderna as Chief Information Officer in July 2013, John served as Vice President of Research and Development Information at AstraZeneca. As a member of the global R&D and IS leadership teams, he was responsible for R&D Informatics, Information, and IS capabilities across the R&D pipeline supporting discovery research, translational sciences, clinical operations, personalized healthcare, CMC, regulatory, and payer functions. Previously, John served as Vice President, Pharmaceutical R&D at Johnson & Johnson in multiple roles including Head of Integrative Neuroscience and Biomarkers, Head of the R&D Informatics Center of Excellence, Co-Founder of the Companion Diagnostic Center of Excellence, and Head of Global R&D IT functions across the J&J pharmaceutical operating companies. Prior to this, John held executive leadership positions at Lilly and Celera Genomics delivering IT and Informatics solutions to accelerate R&D productivity. And before this, he served in program and director roles at Sun Microsystems and Los Alamos National Laboratory leading efforts in high-performance computing, the simulation of complex systems, and scalable software and systems engineering.
After graduating Summa Cum Laude with a B.S. in Mathematics from Rensselaer Polytechnic Institute, John received his Master of Business Administration from the Kellogg School of Management at Northwestern University and a Ph.D. in Applied and Computational Mathematics from Princeton University. He is a regularly invited speaker and presenter at leading industry events, including the Big Data in Pharma Forum, the Bio-IT World Conference and Expo, and the Industrial Research Institute Summit.
Paula is a global strategic and operating management executive with over 20 years’ success at building high-performance global teams, leading complex development programs from early stage through approval, and launching global products. Prior to joining Moderna, Paula was the Vice President and General Manager of Genzyme’s Global Cardiovascular business. She was responsible for the development and commercialization of multiple therapeutics across Renal, Transplant & Oncology, Rare Disease, and Cardiovascular. During her tenure at Genzyme, she was instrumental in advancing new compounds from discovery through clinical development and commercialization with significant roles driving product strategy, portfolio, program and alliance management, sales and marketing and business development. Additionally, Paula led strategic manufacturing capacity planning, supply chain development, and manufacturing process development.
Prior to Genzyme, Paula was a bioprocess engineering consultant for various biopharmaceutical companies. She serves on the Board of Directors of uniQure B.V, a world leader in human gene therapy; the Board of Directors of JFYNet, a non-profit education organization; and the Advisory Board of the Tufts University Chemical and Biological Engineering Department. She is a member of the Healthcare Business Women’s Association and serves as a mentor. Paula earned her B.S. and M.S. in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia. She is a past honoree of Mass High Tech’s Women to Watch.